Skip to main content
Cutia Therapeutics logo

Cutia Therapeutics — Investor Relations & Filings

Ticker · 2487 ISIN · KYG2606C1006 HKEX Manufacturing
Open in API
Filings indexed 178 across all filing types
Latest filing 2023-12-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2487

About Cutia Therapeutics

http://www.cutiatx.com

Cutia Therapeutics is an R&D-driven biopharmaceutical platform established in 2019, specializing in the research, development, manufacture, and commercialization of dermatological treatments. The company is dedicated to providing a comprehensive suite of innovative, safe, and effective solutions for patients and consumers. Its core therapeutic focus areas include the management of localized adipose accumulation and various scalp diseases. As a dermatology-focused entity, Cutia maintains a dedicated pipeline emphasizing novel candidates, including those targeting the Immune System domain.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIALS OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED AT THE 18TH CDA ANNUAL MEETING
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the results of Phase III clinical trials for two products. It is not a financial report, earnings release, or regulatory filing related to financial performance. The content focuses on clinical trial results and business updates rather than financial data or governance. The document is longer than 5,000 characters and contains detailed information about clinical trial outcomes, but it is clearly an announcement of business progress rather than a formal report like an Annual Report or Interim Report. It does not fit into categories related to financial statements, governance, or capital changes. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2023-12-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for the month ended 30 November 2023. It details movements in authorized and issued share capital, share options, and confirmations related to securities issued. The document is regulatory in nature, providing updates on share capital and share movements, but it is not a financial report, earnings release, or management discussion. It is a regulatory filing required by the exchange to disclose share capital changes and confirmations. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (8393 characters) and content confirm it is a detailed regulatory submission rather than a brief announcement or a full financial report.
2023-12-06 English
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION COMPLETED DATABASE LOCK
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the completion of the database lock for a Phase I clinical trial of a drug candidate. It is an update on business progress and clinical trial status, not a financial report, regulatory filing, or meeting-related document. The text is relatively short (2939 characters) and does not contain financial statements, voting results, or management changes. It is an operational update about clinical trial progress, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content and the voluntary announcement label, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2023-11-27 English
OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 AND THIRD QUARTER OF 2023
Regulatory Filings Classification · 85% confidence The document is an announcement by the board of directors providing an operational update on sales performance for the nine months ended 30 September 2023 and the third quarter of 2023. It explicitly states that the data are preliminary, unaudited, and do not represent the full financial performance. The document is relatively short (2583 characters) and serves as an update rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). It also does not fit other categories like Earnings Release (ER) because it lacks key highlights of quarterly results, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it provides substantive operational data. The best fit is Capital/Financing Update (CAP) as it provides an operational update with financial figures related to sales performance, which is often included in such updates. However, since it is more of an operational update without financing or capital structure changes, the fallback category Regulatory Filings (RNS) could be considered. Given the content and context, the most appropriate classification is Regulatory Filings (RNS) with moderate confidence due to the nature of the announcement and its content.
2023-11-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities for an equity issuer listed on the Hong Kong Stock Exchange, including information on authorised share capital, issued shares, share options, and confirmations related to securities issuance. It is a regulatory compliance filing related to share capital and securities movements rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management analysis but serves as a formal regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS). The document length (8390 characters) and detailed tabular data support this classification rather than a brief announcement or a full financial report.
2023-11-03 English
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) IN CHINA REACHED PRIMARY ENDPOINT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the successful completion of a Phase I clinical trial for a drug candidate CU-40101. It provides detailed clinical trial results, safety profile, and pharmacokinetic data. There is no indication that this is a financial report, regulatory filing, or any other formal report type such as Annual Report, Interim Report, or Earnings Release. The document is an announcement of a business development related to clinical trials, not related to financial or governance matters. It does not fit into categories like Legal Proceedings, M&A, or Capital Updates. Given the content and nature, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-11-02 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.